Comments
Zydus Lifesciences Ltd with its subsidiaries received final approval from the United States Food and Drug Administration (USFDA) for Cyclophosphamide Capsules USP in 25 mg and 50 mg formulations.
Cyclophosphamide, a chemotherapy medication known for slowing the growth of cancer cells, is effective in treating various cancers such as lymphoma, myeloma, leukemia, breast cancer, and ovarian cancer. The approved drug will be manufactured at Zydus’ formulation manufacturing facility located in Ahmedabad SEZ, India.
The annual sales of Cyclophosphamide Capsules USP, 25 mg and 50 mg, in the United States were reported to be $6 million as of October 2023. The company reported that with this approval, Zydus expanded its oncology medication portfolio, contributing to its growing list of 383 approvals and over 448 ANDAs filed.
The shares were up by 0.93 per cent to ₹643.00 at 2:26 pm on the BSE.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.